Key facts
- OncoLens’s last known valuation is $54.0M.
- It has raised $22.9M; the latest was Later Stage VC ($15.0M) in Oct 2024.
- Notable investors include Martin Ventures, Atlanta Technology Angels, BIP Ventures, Cross Border Impact Ventures, Robbins Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for OncoLens
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoLens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoLens
Developer of a HIPAA-compliant mobile and web-based platform designed for targeted treatment planning and confident clinical decision-making. The company's platform brings disparate data sets, oncology care teams, and stakeholders into a singular platform to drive multidisciplinary treatment planning, life-science commercial and clinical efforts, and payer authorizations, enabling the physicians to create a tumor board and discuss treatment plans for cancer patients.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2017
- Employees
- 28
- Website
- oncolens.com/
- Ownership
- Privately Held (backing)
OncoLens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoLens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoLens in its N-PORT filings yet. We sweep new filings monthly.